The TIDE shaping the CRISPR community in Copenhagen

With CRISPR-based gene editing rapidly expanding from fundamental research to the clinic, the path from discovery to patient requires more than good science; it requires the right tools, shared standards, and collaborative efforts.

Our Chief Scientific Officer, Lorenzo Bombardelli, recently attended the "world's largest" CRISPR Medicine Conference in Copenhagen, which showed the true collaborative spirit of the CRISPR community. The 500 attendees, 70 speakers, and 150 poster presenters at the conference gathered with a purpose in mind: to coordinate CRISPR efforts and optimize gene-editing applications.

Several projects presented during the event embodied that spirit, such as the GenE-HumDi (Gene Editing for the treatment of Human Diseases), a European consortium working to standardize CRISPR therapies across the full path to the patient, and the newly launched European Genomic Medicine Consortium, a hub connecting researchers and clinicians across genetic and genomic medicine.

Lorenzo kicked off his presentation by highlighting how multiple labs have already adopted TIDE, which has been benchmarked against alternative technologies. For example, we have seen how the simplicity of Sanger-based TIDE analysis sometimes trumps next-generation sequencing, even in regulatory contexts.

He then introduced his audience to the future of TIDE: simulated allele decomposition. Using trace simulation, users simulate sequence traces from candidate edited alleles, either individually or in combination. The experimental data are then compared with the simulated traces, yielding similarity scores and coefficient values that reflect the relative contribution of each allele combination, ranked by how well they explain the observed trace.

The new algorithms based on thousands of training data files enable increasingly diverse and refined analyses. Besides quantifying indel compositions at specific DNA-editing sites, researchers can use TIDE to reliably evaluate experimental data on base editing and homology-directed repair.

This is the intersection TIDE Genetics wants to belong to, as a developer and provider of critical scientific tools that make gene editing smoother and faster while maintaining accuracy.

The work of keynote speaker Dr. Paula Rio and her group at CIEMAT in Madrid illustrates the growing clinical importance of precise gene correction. Their work on Fanconi anemia, a condition caused by specific point mutations in several genes, exemplifies a situation where base editing is preferred over indels induced by double-strand breaks. As future therapies move into clinical trials, researchers need reliable tools to assess precise gene-editing outcomes. Paula's work is a reminder of the impressive progress in gene-editing tools and of the need to keep up with evolving clinical needs. Of course, editing efficiency is only one piece of the puzzle, and delivery and off-targets remain major hurdles.

On the regulatory front, the news is encouraging. The U.S. Food and Drug Administration (FDA) released new guidelines on the use of next-generation sequencing to assess off-target effects. The guidelines clarify how many off-targets need to be verified and with which technologies before regulatory submission. This enables the development of focused, gene-specific assays to track off-targets, putting TIDE in a good position to offer exactly that: tight, simple assays for problematic off-targets. But before any of that, researchers need to know their edits are working as intended, and we are happy to see TIDE developing in directions that address real-life problems.

The field is organizing itself with purpose, and TIDE intends to be part of that infrastructure.